Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL2522677

CC(C)CC(Nc1ccc(Br)cc1)c1ccc(Cl)cc1.N

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 3/20 0.41
KMT2A Q03164 8/20 0.39
MEN1 O00255 6/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 5/20 0.38
LMNA P02545 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
TP53 P04637 2/20 0.38
GAA P10253 2/20 0.38
XBP1 P17861 1/20 0.38
CYP3A4 P08684 2/20 0.37
MAPK1 P28482 2/20 0.37
ALDH1A1 P00352 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
ALOX12 P18054 1/20 0.37
HIF1A Q16665 1/20 0.37
HSD17B10 Q99714 1/20 0.37
NPSR1 Q6W5P4 3/20 0.37
HTT P42858 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2522674 0.81 KMT2A (0.43) CNR1KMT2AMEN1POLBMAPT
SCHEMBL27783636 0.80 CNR1 (0.48) CNR1KMT2AMEN1POLBMAPT
SCHEMBL2520853 0.80 CNR1 (0.44) CNR1KMT2AMEN1POLBMAPT
SCHEMBL15325739 0.75 ALDH1A1 (0.61) KMT2AMEN1MAPTLMNASMN1; SMN2
SCHEMBL433745 0.73 ADRB2 (0.43) KMT2AMEN1LMNASMN1; SMN2TP53
SCHEMBL25068845 0.68 CNR1 (0.46) CNR1KMT2AMEN1MAPTLMNA
SCHEMBL2521895 0.67 ALDH1A1 (0.53) CNR1KMT2AMEN1POLBLMNA
SCHEMBL28305748 0.67 ALDH1A1 (0.53) CNR1KMT2AMEN1POLBLMNA
SCHEMBL17604121 0.66 CNR1 (0.44) CNR1KMT2AMEN1POLBMAPT
SCHEMBL10694751 0.65 MAPT (0.48) CNR1KMT2AMEN1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895566-B2 5H-cyclopenta[d]pyrimidines as AKT protein kinase inhibitors ARRAY BIOPHARMA INC. (US) 2014-11-25 US disclosed
US-20130085135-A1 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS GENENTECH, INC. (US) 2013-04-04 US disclosed
US-8329709-B2 5H-cyclopenta[D]pyrimidines as AKT protein kinase inhibitors GENENTECH, INC. (US) 2012-12-11 US disclosed
US-20110251181-A1 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS GENENTECH, INC. (US) 2011-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085135-A1 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS PIK3CA, AKT3, AKT2 CNR1 3210/4885KMT2A 4172/4885MEN1 3499/4885
US-20110251181-A1 5H-CYCLOPENTA[D]PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS AKT3, PIK3CA, AKT2 CNR1 3036/4885KMT2A 4150/4885MEN1 3565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.